Physician profile
William B Ellison
NPI 1356307318
$4,410.11
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,328 · 2020: $526 · 2021: $827 · 2022: $461 · 2023: $1,126 · 2024: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $528 · Food and Beverage: $463 · Consulting Fee: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $528.03 |
| Food and Beverage | $462.52 |
| Consulting Fee | $278.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $1,155.32 | 2019-2023 | Ffrct |
| Janssen Pharmaceuticals, INC | $406.62 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $388.12 | 2019-2022 | |
| Amgen INC. | $315.72 | 2019-2022 | |
| Pfizer INC. | $263.58 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $218.18 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $196.31 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $174.28 | 2019-2021 | |
| Abbott Laboratories | $139.67 | 2019-2022 | |
| Livanova USA, INC. | $134.28 | 2021 | |
| Abiomed | $126.17 | 2024 | Impella |
| Boston Scientific Corporation | $125.00 | 2019 | |
| Cms Imaging, INC. | $93.53 | 2022 | |
| Astellas Pharma US INC | $89.36 | 2019-2020 | |
| Spacelabs Healthcare INC | $70.64 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $52.58 | 2019-2022 | |
| Cvrx, INC. | $50.96 | 2021 | |
| Cardinal Health 200 LLC | $50.61 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $49.32 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $48.96 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $43.64 | 2019-2020 | |
| Kiniksa Pharmaceuticals, LTD. | $36.60 | 2021 | |
| Esperion Therapeutics, INC. | $33.93 | 2021-2022 | |
| Ge Healthcare | $31.27 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.98 | 2020-2022 | |
| Daiichi Sankyo INC. | $16.51 | 2024 | Vanflyta |
| Atricure, INC. | $14.28 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.11 | 2020 | |
| Amarin Pharma, INC. | $13.59 | 2020 | |
| Merck Sharp & Dohme LLC | $13.11 | 2021 | |
| Genentech USA, INC. | $12.88 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Ellison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.